Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: An open randomized, non-inferiority, trial

Malaria Journal

Volumn 9, Issue 1, 2010, Pages

  Awab, Ghulam Rahim ^a,b   Pukrittayakamee, Sasithon ^a   Imwong, Mallika ^a   Dondorp, Arjen M ^a,c   Woodrow, Charles J ^a,d   Lee, Sue Jean ^a,c   Day, Nicholas Pj ^a,c   Singhasivanon, Pratap ^a   White, Nicholas J ^a,c   Kaker, Faizullah ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Ministry of Public Health   (Afghanistan)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; DNA; HEMOGLOBIN; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROQUINGHAOSU; PIPERAQUINE; QUINOLINE DERIVATIVE;

ADOLESCENT; ADULT; AFGHANISTAN; AGED; ANEMIA; ARM; ARTICLE; ASIA; BLOOD; CHILD; CLEARANCE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; DNA EXTRACTION; DRUG EFFICACY; DRUG TOLERABILITY; ENDEMIC DISEASE; FEMALE; FEVER; FILM; FOLLOW UP; HEADACHE; HUMAN; HYPOTHESIS; INCIDENCE; INFANT; INFECTION; JAUNDICE; LEUKOCYTE COUNT; LOG RANK TEST; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PARASITE; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PROPHYLAXIS; PRURITUS; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT INFECTION; REGISTRATION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SAMPLE SIZE; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; ISOLATION AND PURIFICATION; PARASITOLOGY; PRESCHOOL CHILD; PROSPECTIVE STUDY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; AFGHANISTAN; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALARIA, VIVAX; MALE; MULTIVARIATE ANALYSIS; PLASMODIUM VIVAX; PROSPECTIVE STUDIES; QUINOLINES; RECURRENCE; TREATMENT OUTCOME;

EID: 77951054683     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-105     Document Type: Article

References (41)

1. Vivax malaria: neglected and not benign. RN Price E Tjitra CA Guerra S Yeung NJ White NM Anstey, Am J Trop Med Hyg 2007 77 79 87 18165478
2. The neglected burden of Plasmodium vivax malaria. K Mendis BJ Sina P Marchesini R Carter, Am J Trop Med Hyg 2001 64 97 106 11425182 (Pubitemid 32552576)
3. Effects of Plasmodium vivax malaria in pregnancy. F Nosten R McGready JA Simpson KL Thwai S Balkan T Cho L Hkirijaroen S Looareesuwan NJ White, Lancet 1999 354 546 549 10.1016/S0140-6736(98)09247-2 10470698 (Pubitemid 29381368)
4. Resistance to therapies for infection by Plasmodium vivax. JK Baird, Clin Microbiol Rev 2009 22 508 534 10.1128/CMR.00008-09 19597012
5. A trial of combination antimalarial therapies in children from Papua New Guinea. HA Karunajeewa I Mueller M Senn E Lin I Law PS Gomorrai O Oa S Griffin K Kotab P Suano N Tarongka A Ura D Lautu M Page-Sharp R Wong S Salman P Siba KF Ilett TM Davis, N Engl J Med 2008 359 2545 2557 10.1056/NEJMoa0804915 19064624
6. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. IW Sumawinata Bernadeta B Leksana A Sutamihardja Purnomo B Subianto Sekartuti DJ Fryauff JK Baird, Am J Trop Med Hyg 2003 68 416 420 12875290 (Pubitemid 38230641)
7. Epidemic of Plasmodium falciparum malaria involving substandard antimalarial drugs, Pakistan, 2003. T Leslie H Kaur N Mohammed K Kolaczinski RL Ord M Rowland, Emerg Infect Dis 2009 15 1753 1759 19891862
8. Efficacy of combination therapy with artesunate plus amodiaquine compared to monotherapy with chloroquine, amodiaquine or sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum in Afghanistan. N Durrani T Leslie S Rahim K Graham F Ahmad M Rowland, Trop Med Int Health 2005 10 521 529 10.1111/j.1365-3156.2005.01429.x 15941414 (Pubitemid 40806657)
9. Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan. K Kolaczinski N Durrani S Rahim M Rowland, Trans R Soc Trop Med Hyg 2007 101 1081 1087 10.1016/j.trstmh.2007.06.015 17707447 (Pubitemid 47440537)
10. Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial. T Leslie MI Mayan MA Hasan MH Safi E Klinkenberg CJ Whitty M Rowland, JAMA 2007 297 2201 2209 10.1001/jama.297.20.2201 17519409 (Pubitemid 47010877)
11. Sulfadoxine-pyrimethamine remains efficacious against uncomplicated, Plasmodium falciparum malaria in north-eastern Afghanistan. N Ezard P Nellepalli AW Asha, Ann Trop Med Parasitol 2004 98 85 88 10.1179/000349804225003019 15000735 (Pubitemid 38210469)
12. Molecular surveillance of Plasmodium vivax dhfr and dhps mutations in isolates from Afghanistan. S Zakeri M Afsharpad F Ghasemi A Raeisi N Safi W Butt H Atta ND Djadid, Malar J 9 75 10.1186/1475-2875-9-75 20226087
13. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. MB Denis TM Davis S Hewitt S Incardona K Nimol T Fandeur Y Poravuth C Lim D Socheat, Clin Infect Dis 2002 35 1469 1476 10.1086/344647 12471565 (Pubitemid 36020689)
14. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. A Ratcliff H Siswantoro E Kenangalem R Maristela RM Wuwung F Laihad EP Ebsworth NM Anstey E Tjitra RN Price, Lancet 2007 369 757 765 10.1016/S0140-6736(07)60160-3 17336652 (Pubitemid 46335820)
15. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. AR Hasugian HL Purba E Kenangalem RM Wuwung EP Ebsworth R Maristela PM Penttinen F Laihad NM Anstey E Tjitra RN Price, Clin Infect Dis 2007 44 1067 1074 10.1086/512677 17366451 (Pubitemid 46580274)
16. Malaria reemergence in northern Afghanistan. MK Faulde R Hoffmann KM Fazilat A Hoerauf, Emerg Infect Dis 2007 13 1402 1404 18252122 (Pubitemid 47510312)
17. Malaria and its control in Afghanistan (1950-1954). SL Dhir A Rahim, Indian J Malariol 1957 11 73 126 13438535
18. Malaria control in Afghanistan: progress and challenges. J Kolaczinski K Graham A Fahim S Brooker M Rowland, Lancet 2005 365 1506 1512 10.1016/S0140-6736(05)66423-9 15850637 (Pubitemid 40591697)
19. Spatial epidemiology of Plasmodium vivax, Afghanistan. S Brooker T Leslie K Kolaczinski E Mohsen N Mehboob S Saleheen J Khudonazarov T Freeman A Clements M Rowland J Kolaczinski, Emerg Infect Dis 2006 12 1600 1602 17176583 (Pubitemid 44570910)
20. World Malaria Report, Afghanistan. http://www.emro.who.int/rbm/ CountryProfiles-AFG.htm
21. Epidemiology of Plasmodium falciparum and P. vivax malaria endemic in northern Afghanistan. MK Faulde R Hoffmann KM Fazilat A Hoerauf, J Egypt Soc Parasitol 2008 38 679 692 19209754
22. Severe and complicated malaria. WHO, Trans R Soc Trop Med Hyg 2000 94 Suppl 1 1 90 10748883
23. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. K Stepniewska NJ White, Malar J 2006 5 127 10.1186/1475-2875-5-127 17187673 (Pubitemid 46127298)
24. Therapeutic responses to different antimalarial drugs in vivax malaria. S Pukrittayakamee A Chantra JA Simpson S Vanijanonta R Clemens S Looareesuwan NJ White, Antimicrob Agents Chemother 2000 44 1680 1685 10.1128/AAC.44.6.1680-1685. 2000 10817728 (Pubitemid 30340814)
25. Analysing Survival Data from Clinical Trials and Observational Studies. E Marubini MG Valsecchi, Chichester: John Wiley & Sons 1995
26. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. G Piaggio DR Elbourne DG Altman SJ Pocock SJ Evans, JAMA 2006 295 1152 1160 10.1001/jama.295.10.1152 16522836 (Pubitemid 43352345)
27. Detection and identification of the four malaria parasite species infecting humans by PCR amplification. G Snounou, Methods Mol Biol 1996 50 263 291 8751365
28. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. NJ White, Trans R Soc Trop Med Hyg 1994 88 Suppl 1 41 43 10.1016/0035-9203(94)90471-5 8053024
29. In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. JK Baird I Wiady DJ Fryauff MA Sutanihardja B Leksana H Widjaya Kysdarmanto B Subianto, Am J Trop Med Hyg 1997 56 627 631 9230793 (Pubitemid 27318584)
30. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. A Ratcliff H Siswantoro E Kenangalem M Wuwung A Brockman MD Edstein F Laihad EP Ebsworth NM Anstey E Tjitra RN Price, Trans R Soc Trop Med Hyg 2007 101 351 359 10.1016/j.trstmh.2006.06.008 17028048 (Pubitemid 46205894)
31. Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia. I Sutanto S Suprijanto Nurhayati P Manoempil JK Baird, Am J Trop Med Hyg 2009 81 338 342 19635895
32. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. N Chen A Auliff K Rieckmann M Gatton Q Cheng, J Infect Dis 2007 195 934 941 10.1086/512242 17330782 (Pubitemid 46452097)
33. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. M Imwong G Snounou S Pukrittayakamee N Tanomsing JR Kim A Nandy JP Guthmann F Nosten J Carlton S Looareesuwan S Nair D Sudimack NP Day TJ Anderson NJ White, J Infect Dis 2007 195 927 933 10.1086/512241 17330781 (Pubitemid 46452096)
34. Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan. M Rowland N Durrani, Trans R Soc Trop Med Hyg 1999 93 641 643 10.1016/S0035- 9203(99)90081-0 10717755 (Pubitemid 30015794)
35. Compliance with 14-day primaquine therapy for radical cure of vivax malaria - a randomized placebo-controlled trial comparing unsupervised with supervised treatment. T Leslie MA Rab H Ahmadzai N Durrani M Fayaz J Kolaczinski M Rowland, Trans R Soc Trop Med Hyg 2004 98 168 173 10.1016/S0035-9203(03) 00041-5 15024927 (Pubitemid 38949897)
36. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. T Leslie I Mayan N Mohammed P Erasmus J Kolaczinski CJ Whitty M Rowland, PLoS One 2008 3 2861 10.1371/journal.pone.0002861 18682739
37. Naturally acquired immunity to vivax malaria. C Luxemburger F Nosten NJ White, Lancet 1999 354 162 10.1016/S0140-6736(05)75295-8 10408515 (Pubitemid 29313165)
38. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. S Pukrittayakamee M Imwong S Looareesuwan NJ White, Acta Trop 2004 89 351 356 10.1016/j.actatropica.2003.10.012 14744561 (Pubitemid 38117071)
39. The assessment of antimalarial drug efficacy. NJ White, Trends Parasitol 2004 18 351 356
40. Pitfalls in estimating piperaquine elimination. J Tarning N Lindegardh A Annerberg T Singtoroj NP Day M Ashton NJ White, Antimicrob Agents Chemother 2005 49 5127 5128 10.1128/AAC.49.12.5127-5128.2005 16304183 (Pubitemid 41778931)
41. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. HA Karunajeewa KF Ilett I Mueller P Siba I Law M Page-Sharp E Lin J Lammey KT Batty TM Davis, Antimicrob Agents Chemother 2008 52 237 243 10.1128/AAC.00555-07 17967917